# A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Source: https://onco.cc/trials/nct07629960/  
OnCo record `nct07629960` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BLU-924 in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Blueprint Medicines Corporation, now recruiting.

## Summary

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations is a phase 1/2 interventional study registered as NCT07629960 by Blueprint Medicines Corporation, with 265 participants planned, started 2026-06-04 and due to reach its primary completion in 2029-09. Interventions recorded: BLU-924.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07629960
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants With Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations
- Sponsor: Blueprint Medicines Corporation
- Enrolled: 265

## Sources

- ClinicalTrials.gov NCT07629960: https://clinicaltrials.gov/study/NCT07629960

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Blueprint Medicines](https://onco.cc/companies/blueprint-medicines/), [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct07629960.json